Drug Search Results
More Filters [+]

Aceclidine

Alternative Names: aceclidine
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Aceclidine has been marketed in Europe but has not been used clinically in the United States. It is used in the treatment of open-angle glaucoma and is a parasympathomimetic agent.

Mechanisms of Action: mAChR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Germany | Greece | Italy | Peru | Portugal

Approved Indications: None

Known Adverse Events: None

Company: Ji Xing Pharmaceuticals (Shanghai)
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aceclidine

Countries in Clinic: China, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Miosis|Presbyopia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

JX07001

P3

Active, not recruiting

Miosis|Presbyopia

2024-08-19

JX07002

P1

Completed

Presbyopia

2024-04-10

21%

Safety Study

P3

Completed

Miosis|Presbyopia

2024-02-09

CLARITY

P3

Completed

Presbyopia|Miosis

2023-12-15

Recent News Events